MONOCLONAL T LYMPHOCYTE FACTOR REGULATION OF MYELOMA

MOPC-315是一种抗TNP-IgA分泌的BALB/c浆细胞瘤 它由类淋巴细胞，非分泌细胞，IgA 315- 分泌浆细胞样细胞和中间细胞。在进站期间 体内生长淋巴细胞型、非分泌型315细胞增殖 并分化为分泌IgA 315的浆细胞样细胞。 生长和分化可以在体内和体内调节 通过载体特异性辅助子、抑制子和反抑制子进行体外实验 T细胞。某些分化调节T细胞的特异性 不仅能识别携带者抗原，还能识别IgA315独特位。这个 这里描述的实验涉及生产和 绵羊单克隆性T细胞系的鉴定 红细胞(SRBC)免疫BALB/c小鼠，可增强， 抑制，相反地抑制生长或分泌 MOPC-315细胞体外分化的研究因为在体内和体内 体外实验表明，由于T细胞的作用，调节正在发生 细胞释放的可溶性调节因子，这笔赠款也是 专注于提纯、生化和血清学 对调控因素进行表征。这是特别的 重要的是因为所有的调节细胞似乎都作用于 MOPC-315的非分泌性类淋巴细胞群 通过任一表面IgA 315独特位与细胞相互作用 或通过表面IgA315结合TNP-SRBC。因此，信息 关于这些因子的结构-功能关系是可能的 为了获得。独特型315-特异性分化辅助T细胞(THD) 细胞，SRBC特异性分化抑制T(TSD)细胞，以及 315独特型特异性分化抑制因子T(TCSD) 已经产生了细胞单克隆系。多克隆THD 细胞可通过以下途径保护小鼠免受MOPC-315肿瘤的生长 通过诱导明显降低细胞的增殖能力 它的差异化。实验旨在确定 Thd细胞抑制小鼠肿瘤生长的机制 纯化的独特型315-和SRBC-对小鼠的免疫效果 特异性THD辅助因子作为治疗MOPC的药物- 315体内细胞的描述。这些实验可能 证明调节性刺激以及细胞毒性 介入可以对某些肿瘤起到治疗作用 进步。

MOPC-315 is an anti-TNP IgA-secreting BALB/c plasmacytoma which is composed of lymphocytoid, non-secretory cells, IgA 315- secreting plasmacytoid cells, and intermediate cells. During in vivo growth the lymphocytoid, non-secretory 315 cells proliferate and differentiate into the IgA 315-secreting plasmacytoid cells. That growth and differentiation can be regulated in vivo and in vitro by carrier-specific helper, suppressor, and contrasuppressor T cells. Some of the differentiation regulating T cells specifically recognize not only carrier antigen but also IgA 315 idiotopes. The experiments described herein involve production and characterization of monoclonal T cell lines from sheep erythrocyte (SRBC)-immune BALB/c mice which can enhance, suppress, or contrasuppress the growth or secretory differentiation of MOPC-315 cells in vitro. Since in vivo and in vitro experiments suggest that regulation is occurring due to T cell release of soluble regulatory factors, this grant also is focused on purification, and biochemical and serological characterization of the regulatory factors. This is particularly important since all of the regulatory cells appear to act on the non-secretory lymphocytoid population of MOPC-315 and appear to interact with the cells through either surface IgA 315 idiotopes or through surface IgA 315 binding TNP-SRBC. Thus, information about structure-function relationships of these factors is possible to obtain. Idiotype 315-specific differentiation helper T (THd) cell, SRBC-specific differentiation suppressor T (Tsd) cell, and idiotype 315-specific differentiation contrasuppressor T (TCSd) cell monoclonal lines have already been produced. Polyclonal THd cells can protect mice against MOPC-315 tumor growth by apparently reducing the cells proliferative potential by inducing its differentiation. Experiments designed to determine the mechanism by which THd cells can inhibit tumor progression in mice and efficacy of using purified idiotype 315- and SRBC- specific THd helper factors as therapeutic drugs against MOPC- 315 cells in vivo are described herein. These experiments may demonstrate that regulatory stimuli as well as cytotoxic intervention can have therapeutic effects on some tumors' progression.